REOLYSIN induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses creating a cancer immunotherapy by actively turning 'COLD' tumors 'HOT'.

What is Immunotherapy?

Immunotherapy is a medical procedure in which certain parts of the immune system are used to treat a disease by enhancing, inducing or suppressing an immune response; for example, to fight cancer. The use of immunotherapy for cancer is also known as immuno-oncology.

What is immuno-oncology?

Immuno-oncology includes therapies that use the body's own immune system to combat cancer cells. While this is what the body's immune system is meant to do, without some help, the therapy doesn't always succeed. Cancer can trick the immune system and overtake cells by disguising itself as normal cells or continuing to mutate so that it stays one step ahead of the body's immune response. Other times, cancers simply grow too quickly for the body's immune response to react.

The aim of immuno-oncology treatments is to activate the body's natural immune system and help it find and target disguised or mutated cancer cells. According to the European Cancer Patient Coalition, evidence from clinical trials suggests the effects of immuno-oncology therapies effects on cancer cells may last for a long time, training the immune system to fight against cancer cells even after remission.

How does REOLYSIN help?

REOLYSIN® is a true immuno-oncology agent that, in addition to causing tumor cell lysis, generates innate and adaptive anti-tumor immune responses. REOLYSIN is a potential treatment for a variety of tumor types.